360° SearchNetwork Hot Spots Trends Time Series

Advanced Search Options >>

Coronado Biosciences Inc

Type: Company

Name: Coronado Biosciences Inc

First reported May 13 2013 - Updated May 13 2013 - 1 reports

Bank of America Corp

CORONADO BIOSCIENCES INC Coverage Initiated by Analysts at Bank of America. (CNDO)

Research analysts at Bank of America began coverage on shares of CORONADO BIOSCIENCES INC (NASDAQ: CNDO)The analysts wrote, ?Coronado?s advisory board include the pioneers of the ‘hygiene hypothesis,? i.e., that many systemic inflammation and autoimmune ... [Published American Banking News - May 13 2013]

Entities: Coronado Biosciences Inc, Bank of America Corp, Stocks

First reported May 08 2013 - Updated May 09 2013 - 2 reports

US Securities and Exchange Commission

Coronado Biosciences Inc. Files SEC Form CT ORDER, Confident. . .

Coronado Biosciences Inc. Files SEC Form CT ORDER, Confidential Treatment Order (Apr. 30, 2013)Pharmaceutical PreparationsNewsRx.comBy a News Reporter-Staff News Editor at Pharma Business Week -- According to news reporting originating from Washington, ... [Published Equities.com - May 08 2013]

Entities: US Securities and Exchange Commission, Coronado Biosciences Inc, Pharmaceutical Preparations, BusinessWeek, Financial Statement

First reported May 08 2013 - Updated May 08 2013 - 5 reports

Coronado Biosciences Reports Financial Results for the First Quarter Ended March 31, 2013

(GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today its financial results for ... [Published BioSpace - May 08 2013]

Entities: Coronado Biosciences Inc, Immunotherapy, Cancer

First reported May 08 2013 - Updated May 08 2013 - 1 reports

CORONADO BIOSCIENCES INC (CNDO) Announces Quarterly Earnings Results, Misses Estimates By $0.05 EPS

CORONADO BIOSCIENCES INC (NASDAQ: CNDO) announced its earnings results on Wednesday. The company reported ($0.35) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.30) by $0.05, reports. During the same quarter in the prior year, ... [Published American Banking News - May 08 2013]

Entities: Coronado Biosciences Inc, Immunotherapy, Canaccord Genuity Corp, Merrill Lynch & Co Inc

First reported May 07 2013 - Updated May 07 2013 - 1 reports

Coronado Biosciences, Inc., Burlington

Thomas F. Schaible was named project leader at Coronado Biosciences, Inc., a biopharmaceutical company in Burlington.... ... [Published Boston Globe - May 07 2013]

Entities: Coronado Biosciences Inc

First reported May 07 2013 - Updated May 07 2013 - 2 reports

Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease

Staying up-to-date has never been simpler. Sign up for the today! BURLINGTON, Mass., May 7, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents ... [Published BioSpace - May 07 2013]

Entities: Inflammatory Bowel Disease, Coronado Biosciences Inc, Doctor of Philosophy

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Merrill Lynch & Co Inc

Coronado Biosciences to Present at the Bank of America (BAC) Merrill Lynch 2013 Health Care Conference

Staying up-to-date has never been simpler. Sign up for the today! BURLINGTON, Mass., May 6, 2013 (GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents ... [Published BioSpace - May 06 2013]

Entities: Coronado Biosciences Inc, Merrill Lynch & Co Inc, Bank of America Corp, Health Care

First reported May 06 2013 - Updated May 06 2013 - 1 reports

Coronado Biosciences announces departure of president

5 minutes ago, 1:08pm (ET) 05/06/2013 DatamonitorCoronado Biosciences, Inc., a biopharmaceutical company, has announced the departure of Bobby Sandage, Jr., president and director of the company."We thank Bobby for his outstanding leadership and tireless ... [Published Zecco - May 06 2013]

Entities: Coronado Biosciences Inc, Crohn's disease, Psoriasis

First reported May 06 2013 - Updated May 06 2013 - 4 reports

CORONADO BIOSCIENCES INC.: Coronado Biosciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference

CORONADO BIOSCIENCES TO PRESENT AT THE BANK OF AMERICA MERRILL LYNCH 2013 HEALTH CARE CONFERENCEBurlington, MA - May 6, 2013 - Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic ... [Published 4 Traders - May 06 2013]

Entities: Coronado Biosciences Inc, Bank of America Merrill Lynch, Health Care, Immunotherapy, Trichuris suis

First reported May 01 2013 - Updated May 01 2013 - 2 reports

CORONADO BIOSCIENCES INC. : Coronado Biosciences to Report First Quarter 2013 Financial Results

CORONADO BIOSCIENCES TO REPORT FIRST QUARTER 2013 FINANCIAL RESULTSConference Call Scheduled for May 8, 2013Burlington, MA - May 1, 2013 - Coronado Biosciences, Inc. (NASDAQ: CNDO), a biopharmaceutical company focused on the development of novel immunotherapy ... [Published 4 Traders - May 01 2013]

Entities: Coronado Biosciences Inc, Immunotherapy, Trichuris suis

First reported Apr 29 2013 - Updated Apr 29 2013 - 2 reports

Coronado Biosciences Announces Sale of Common Stock in Its At-the-Market Public Offering

(GLOBE NEWSWIRE) -- Coronado Biosciences, Inc. (Nasdaq:CNDO), a biopharmaceutical company focused on the development of novel immunotherapy biologic agents for the treatment of autoimmune diseases and cancer, announced today that it has sold through its ... [Published Automotive Technology - Apr 29 2013]

Entities: Coronado Biosciences Inc, Common Shares, JENNISON Assoc LLC, US Securities and Exchange Commission, Immunotherapy

First reported Apr 23 2013 - Updated Apr 23 2013 - 1 reports

CORONADO BIOSCIENCES INC Coverage Initiated at Merrill Lynch (CNDO)

Research analysts at Merrill Lynch began coverage on shares of CORONADO BIOSCIENCES INC (NASDAQ: CNDO) CORONADO BIOSCIENCES INC (NASDAQ: CNDO) traded up 10.93% on Monday, hitting $11.87. CORONADO BIOSCIENCES INC has a 52-week low of $4.00 and a 52-week ... [Published American Banking News - Apr 23 2013]

Entities: Coronado Biosciences Inc, Merrill Lynch & Co Inc, Earnings Per Share, Immunotherapy, Canaccord Genuity Corp

Quotes

"We have also strengthened our financial position during this quarter," continued Dr. Weisman. "From January 1, 2013 through May 7, 2013, we sold an aggregate of approximately 3.4 million shares of our common stock under our at-the-market sales facilities for net proceeds of approximately $29.9 million."

CORONADO BIOSCIENCES INC.: Coronado Biosciences Reports Financial Results for the First Quarter E ... [Published 4 Traders - May 08 2013]

"We are excited that Dr. Schaible has joined us in developing TSO for IBD," said Dr. Harlan F Weisman, Coronado's Chairman and CEO. "Dr. Schaible led the efforts at Johnson & Johnson JNJ) in getting REMICADE(R) (infliximab) approved for Crohn's disease and rheumatoid arthritis. His extensive development and regulatory experience in IBD and other autoimmune conditions will be instrumental to progressing TSO forward. We believe the fact that we are able to attract someone with Dr. Schaible's credentials is a testament of the interest in the hygiene hypothesis within the field of immunology and TSO's potential to be a game changer for patients with IBD and other autoimmune diseases."

Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Dis ... [Published Individual.com - May 07 2013]

...leadership and tireless efforts in helping to bring Coronado to where we are today," said Dr Harlan F Weisman, Coronado's Chairman and CEO. "Bobby was responsible for building the initial management team, securing several rounds of financing, taking the company public and successfully advancing Coronado's exciting clinical stage pipeline. We wish him much success in his future endeavors. Moving forward, we anticipate results from TSO's two Phase II trials in Crohn's disease in the second half of this year, and potentially data from investigator-initiated autism and psoriasis studies, and we remain committed to continuing our momentum throughout 2013 and thereafter."

Coronado Biosciences announces departure of president [Published Zecco - May 06 2013]

...Hartmann. "Our laboratory has spent the past few years focusing on the area of autoimmunity and novel ideas around nematode-host interactions, and is eager to embark on this challenging, and potentially rewarding, scientific venture."

Coronado Biosciences Signs Research Collaboration and License Agreement With Freie Universitat Be ... [Published GlobeNewswire - Feb 22 2013]

More Content

sort by: Date \| Relevance
CORONADO BIOSCIENCES INC Coverage Initiated by ... [Published American Banking News - May 13 2013]
Corrections [Published Austin American Statesman - May 11 2013]
Volume in Focus: Synta Pharmaceuticals Corp.(NA... [Published SBWire - May 09 2013]
Coronado Biosciences Inc's net loss widens to U... [Published Zecco - May 09 2013]
Coronado Biosciences Inc. Files SEC Form CT ORD... [Published Equities.com - May 08 2013]
Coronado Biosciences Inc. Files SEC Form 424B5,... [Published Equities.com - May 08 2013]
Four development-stage drug companies report ea... [Published Boston Business Journal - May 08 2013]
Coronado Biosciences' CEO Discusses Q1 2013 Res... [Published Seeking Alpha - May 08 2013]
Coronado Biosciences Reports Financial Results ... [Published BioSpace - May 08 2013]
CORONADO BIOSCIENCES INC (CNDO) Announces Quart... [Published American Banking News - May 08 2013]
CORONADO BIOSCIENCES INC.: Coronado Biosciences... [Published 4 Traders - May 08 2013]
Coronado Biosciences (CNDO): Q1 EPS of -$0.35 m... [Published Seeking Alpha - May 08 2013]
Coronado Biosciences Reports Financial Results ... [Published GlobeNewswire: Acquisitions News - May 08 2013]
Coronado Biosciences Reports Financial Results ... [Published TheStreet.com - May 08 2013]
Coronado Biosciences Reports Financial Results ... [Published Stockwatch - May 08 2013]
Coronado Biosciences Reports Financial Results ... [Published Individual.com - May 08 2013]
Coronado Biosciences, Inc., Burlington [Published Boston Globe - May 07 2013]
Coronado Biosciences Appoints Thomas F. Schaibl... [Published BioSpace - May 07 2013]
Coronado Biosciences Appoints Thomas F. Schaibl... [Published GlobeNewswire: Acquisitions News - May 07 2013]
Coronado Biosciences Appoints Thomas F. Schaibl... [Published Individual.com - May 07 2013]
Coronado Biosciences to Present at the Bank of ... [Published BioSpace - May 06 2013]
Coronado Biosciences announces departure of pre... [Published Zecco - May 06 2013]
Holy Name Patients Swallowing Parasitic Eggs to... [Published Teaneck NJ Patch - May 06 2013]
CORONADO BIOSCIENCES INC.: Coronado Biosciences... [Published 4 Traders - May 06 2013]
Coronado Biosciences to Present at the Bank of ... [Published GlobeNewswire: Acquisitions News - May 06 2013]
Coronado Biosciences to Present at the Bank of ... [Published Yahoo! Finance - May 06 2013]
Coronado Biosciences to Present at the Bank of ... [Published Reuters - May 06 2013]
Coronado Biosciences to Present at the Bank of ... [Published Street Insider - May 06 2013]
CORONADO BIOSCIENCES INC. : Coronado Bioscience... [Published 4 Traders - May 01 2013]
Coronado Biosciences to Report First Quarter 20... [Published GlobeNewswire: Acquisitions News - May 01 2013]

Blogs

sort by: Date \| Relevance
Financings of the Fortnight Keeps Its Dauber Up [Published The IN VIVO Blog - Apr 18 2013] Baseball fanatics out there might remember Roger Craig, a pitcher for the hapless expansion 1962 New York Metropolitans, then much later the manager of several memorable San Francisco Giants teams in the 1980s. As the San Fran skipper, Craig was a ...
4 Healthcare Stock Stories for Wednesday Wellness [Published Wall St. Cheat Sheet - Jan 23 2013] Johnson & Johnson ( NYSE:JNJ ): Current price $72.79 Johnson & Johnson said that it will present its Medical Devices & Diagnostics division strategy for accelerating growth during its yearly Business Review. MD&D comprised around 41 percent of the ...
Up And Down The Ladder… Job Changes [Published Pharmalot - Jan 04 2013] Hired someone new and exciting? Promoted a rising star? Finally solved that hard-to-fill spot? Share the news with us and we’ll share with it others. That’s right. Send us your announcements and we’ll find a home for them . Don’t be shy. Everyone wants ...

Press Releases

sort by: Date \| Relevance
Coronado Biosciences Reports Financial Results ... [Published GlobeNewswire: Acquisitions News - May 08 2013]
Coronado Biosciences Appoints Thomas F. Schaibl... [Published GlobeNewswire: Acquisitions News - May 07 2013]
Coronado Biosciences to Present at the Bank of ... [Published GlobeNewswire: Acquisitions News - May 06 2013]
Coronado Biosciences to Report First Quarter 20... [Published GlobeNewswire: Acquisitions News - May 01 2013]
Coronado Biosciences Announces Departure of Dr.... [Published GlobeNewswire: Advertising News - Apr 24 2013]